DE60233647D1 - Reduziertes vitamin b2 enthaltende arzneimittel - Google Patents

Reduziertes vitamin b2 enthaltende arzneimittel

Info

Publication number
DE60233647D1
DE60233647D1 DE60233647T DE60233647T DE60233647D1 DE 60233647 D1 DE60233647 D1 DE 60233647D1 DE 60233647 T DE60233647 T DE 60233647T DE 60233647 T DE60233647 T DE 60233647T DE 60233647 D1 DE60233647 D1 DE 60233647D1
Authority
DE
Germany
Prior art keywords
agent
containing medicament
reductant
preventing
reduced vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233647T
Other languages
English (en)
Inventor
Seiichi Araki
Mamoru Suzuki
Yoshiki Sugihara
Toshio Toyosawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of DE60233647D1 publication Critical patent/DE60233647D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60233647T 2001-03-21 2002-03-19 Reduziertes vitamin b2 enthaltende arzneimittel Expired - Lifetime DE60233647D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001080578 2001-03-21
PCT/JP2002/002616 WO2002074313A1 (en) 2001-03-21 2002-03-19 Drugs containing reduced vitamin b¿2?

Publications (1)

Publication Number Publication Date
DE60233647D1 true DE60233647D1 (de) 2009-10-22

Family

ID=18936834

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233647T Expired - Lifetime DE60233647D1 (de) 2001-03-21 2002-03-19 Reduziertes vitamin b2 enthaltende arzneimittel

Country Status (6)

Country Link
US (1) US7579325B2 (de)
EP (1) EP1371370B1 (de)
JP (1) JP4278384B2 (de)
AT (1) ATE442143T1 (de)
DE (1) DE60233647D1 (de)
WO (1) WO2002074313A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070014A1 (en) * 2012-11-01 2014-05-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
JP6129395B1 (ja) * 2016-10-29 2017-05-17 誠一 荒木 ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤
JP2018070581A (ja) * 2017-04-19 2018-05-10 誠一 荒木 還元型ビタミンｂ２製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2970995A (en) * 1959-03-20 1961-02-07 Gen Mills Inc Reductive acylated products of riboflavin
HU203198B (en) 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
JP2979767B2 (ja) * 1991-09-09 1999-11-15 味の素株式会社 発酵法によるリボフラビンの製造法
JP3636207B2 (ja) * 1991-09-13 2005-04-06 エーザイ株式会社 免疫賦活・感染防御剤及びその製造方法
NZ244270A (en) 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
DE4328871A1 (de) * 1993-08-27 1995-03-02 Beiersdorf Ag Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis
AU1881095A (en) * 1994-02-28 1995-09-11 James P. Cox Sulfur and oxygen deodorant compositions
US5714469A (en) * 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
US6506792B1 (en) * 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
JP3286831B2 (ja) 1996-04-01 2002-05-27 エーザイ株式会社 ビタミンｂ２含有医薬
JPH09301861A (ja) 1996-05-13 1997-11-25 Showa Denko Kk ラジカル疾患用注射・点滴薬剤
JPH11199486A (ja) * 1998-01-13 1999-07-27 Eisai Co Ltd ビタミンｂ２含有医薬組成物
JPH11199513A (ja) * 1998-01-14 1999-07-27 Eisai Co Ltd 高濃度リン酸リボフラビンナトリウム注射剤
AU747521B2 (en) 1998-03-09 2002-05-16 Takeda Pharmaceutical Company Limited Cycloalkene derivatives, process for producing the same, and use
JP2000080046A (ja) 1998-09-03 2000-03-21 Dai Ichi Seiyaku Co Ltd 多臓器障害の予防・治療剤
JP5073884B2 (ja) 1998-10-09 2012-11-14 三井製糖株式会社 感染予防治療剤、抗エンドトキシン剤、ワクチンアジュバント剤および成長促進剤
JP2000297049A (ja) 1999-04-15 2000-10-24 Mitsui Chemicals Inc アルキルベンゼンの製造方法
JP2000302768A (ja) 1999-04-16 2000-10-31 Sumitomo Pharmaceut Co Ltd ヒドラゾン誘導体
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US20030162751A1 (en) 2001-12-19 2003-08-28 Adam Grobin Pharmaceutical composition comprising 5' monophosphate ester of riboflavin and solubilized riboflavin
US20030161871A1 (en) 2001-12-19 2003-08-28 Geoffrey Hird Solubilized riboflavin
US20030143265A1 (en) 2001-12-19 2003-07-31 Seiichi Araki Method for treatment of sepsis

Also Published As

Publication number Publication date
US20040106562A1 (en) 2004-06-03
ATE442143T1 (de) 2009-09-15
JP4278384B2 (ja) 2009-06-10
EP1371370A1 (de) 2003-12-17
US7579325B2 (en) 2009-08-25
EP1371370A4 (de) 2006-07-26
EP1371370B1 (de) 2009-09-09
JPWO2002074313A1 (ja) 2004-07-08
WO2002074313A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
AP2006003514A0 (en) Piperazine derivatives for the treatment of HIV infections.
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
WO2004005286A3 (en) Viral inhibitors
WO2003080582A3 (de) Fredericamycin-derivate
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
WO2005046603A3 (en) Pyridine compounds
AP2005003350A0 (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases.
HK1128679A1 (en) 1,2-diphenylethene derivatives for treatment of immune diseases 12-
SE0101932D0 (sv) Pharmaceutical combinations
WO2006121964A3 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
MXPA04006041A (es) Antivirales de piridoquinoxalina.
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
WO2002085358A3 (en) Antiviral agents and methods of treating viral infections
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
DE60233647D1 (de) Reduziertes vitamin b2 enthaltende arzneimittel
WO2003024996A3 (de) Antibakterielle makrozyklen
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition